MenoGeniX

Aurora, United States Founded: 2010 • Age: 16 yrs
Drugs for menopause and cancer-related vasomotor symptoms are developed.

About MenoGeniX

MenoGeniX is a company based in Aurora (United States) founded in 2010.. MenoGeniX has raised $1.18 million across 7 funding rounds from investors including HHS. MenoGeniX offers products and services including MNGX-100. MenoGeniX operates in a competitive market with competitors including Amyris, Avidity Biosciences, Arbor Biotechnologies, Univercells and Sutro Biopharma, among others.

  • Headquarter Aurora, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Legal Name Menogenix, Inc
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Health Technology & Digital Health
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $1.18 M (USD)

    in 7 rounds

  • Latest Funding Round
    $299.83 K (USD), Grant

    Jun 01, 2020

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of MenoGeniX

MenoGeniX offers a comprehensive portfolio of products and services, including MNGX-100. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Potential alternative therapy for hot flashes and vasomotor symptoms in menopause

People of MenoGeniX
Headcount 1-10
Employee Profiles 3
Board Members and Advisors 8
Employee Profiles
People
Richard C. Duke
Chairman & CEO
People
Woodruff Emlen
Director & Acting CMO
People
T. Richard Fort
Director

Unlock access to complete

Board Members and Advisors
people
Frans Trouwen
Business Advisor
people
Gladys Monroy
Business Advisor
people
Doug Farrar
Business Advisor
people
Bart CJM Fauser
Scientific Advisor

Unlock access to complete

Funding Insights of MenoGeniX

MenoGeniX has successfully raised a total of $1.18M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $299.83 thousand completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Grant — $299,831
  • First Round

    (30 Jul 2012)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2020 Amount Grant - MenoGeniX Valuation

investors

HHS
Jan, 2018 Amount Grant - MenoGeniX Valuation

investors

HHS
Dec, 2017 Amount Seed - MenoGeniX Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in MenoGeniX

MenoGeniX has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Public health and human services are overseen by HHS.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by MenoGeniX

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - MenoGeniX

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Menogenix Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of MenoGeniX

MenoGeniX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Avidity Biosciences, Arbor Biotechnologies, Univercells and Sutro Biopharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of renewable products for industrial solutions
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Genomic technologies and drug discovery platforms are provided.
domain founded_year HQ Location
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Menogenix

Frequently Asked Questions about MenoGeniX

When was MenoGeniX founded?

MenoGeniX was founded in 2010 and raised its 1st funding round 2 years after it was founded.

Where is MenoGeniX located?

MenoGeniX is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.

Who is the current CEO of MenoGeniX?

Richard C Duke is the current CEO of MenoGeniX.

Is MenoGeniX a funded company?

MenoGeniX is a funded company, having raised a total of $1.18M across 7 funding rounds to date. The company's 1st funding round was a Seed of $75K, raised on Jul 30, 2012.

What does MenoGeniX do?

MenoGeniX was founded in 2010 and is based in Aurora, United States, as a clinical-stage biotechnology company. Treatments for menopause and associated symptoms in breast and prostate cancer patients are developed. The product pipeline features MNGX-100, a reformulated biological therapy with Phase 1b completed in 2014, currently advancing through Phase 2 trials for hot flashes and vasomotor symptoms. Operations focus on drug development in the womens health and oncology sectors.

Who are the top competitors of MenoGeniX?

MenoGeniX's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.

What products or services does MenoGeniX offer?

MenoGeniX offers MNGX-100.

Who are MenoGeniX's investors?

MenoGeniX has 1 investor. Key investors include HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available